Compare Procter & Gamble Health with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs PFIZER - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH PFIZER PROCTER & GAMBLE HEALTH/
PFIZER
 
P/E (TTM) x 42.3 37.2 113.7% View Chart
P/BV x 4.4 6.4 68.5% View Chart
Dividend Yield % 10.9 0.5 2,026.5%  

Financials

 PROCTER & GAMBLE HEALTH   PFIZER
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
PFIZER
Mar-19
PROCTER & GAMBLE HEALTH/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3,5493,840 92.4%   
Low Rs1,3012,080 62.6%   
Sales per share (Unadj.) Rs511.4455.0 112.4%  
Earnings per share (Unadj.) Rs61.393.8 65.4%  
Cash flow per share (Unadj.) Rs74.0109.4 67.7%  
Dividends per share (Unadj.) Rs440.0022.50 1,955.6%  
Dividend yield (eoy) %18.10.8 2,386.8%  
Book value per share (Unadj.) Rs927.8658.2 141.0%  
Shares outstanding (eoy) m16.6045.75 36.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.76.5 72.9%   
Avg P/E ratio x39.631.6 125.4%  
P/CF ratio (eoy) x32.827.1 121.1%  
Price / Book Value ratio x2.64.5 58.1%  
Dividend payout %717.924.0 2,992.3%   
Avg Mkt Cap Rs m40,257135,420 29.7%   
No. of employees `0001.12.6 43.1%   
Total wages/salary Rs m1,3133,238 40.5%   
Avg. sales/employee Rs Th7,486.77,911.4 94.6%   
Avg. wages/employee Rs Th1,157.61,230.9 94.0%   
Avg. net profit/employee Rs Th897.21,630.7 55.0%   
INCOME DATA
Net Sales Rs m8,49020,815 40.8%  
Other income Rs m2441,674 14.6%   
Total revenues Rs m8,73422,489 38.8%   
Gross profit Rs m1,4825,712 25.9%  
Depreciation Rs m211714 29.6%   
Interest Rs m073 0.0%   
Profit before tax Rs m1,5146,599 22.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5632,309 24.4%   
Profit after tax Rs m1,0174,291 23.7%  
Gross profit margin %17.527.4 63.6%  
Effective tax rate %37.135.0 106.2%   
Net profit margin %12.020.6 58.1%  
BALANCE SHEET DATA
Current assets Rs m15,34327,167 56.5%   
Current liabilities Rs m1,9608,917 22.0%   
Net working cap to sales %157.687.7 179.8%  
Current ratio x7.83.0 256.9%  
Inventory Days Days4968 71.9%  
Debtors Days Days2830 94.5%  
Net fixed assets Rs m1,2098,862 13.6%   
Share capital Rs m166458 36.3%   
"Free" reserves Rs m15,23529,656 51.4%   
Net worth Rs m15,40130,113 51.1%   
Long term debt Rs m025 0.0%   
Total assets Rs m17,59539,400 44.7%  
Interest coverage xNM91.5-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.5 91.3%   
Return on assets %5.811.1 52.2%  
Return on equity %6.614.2 46.4%  
Return on capital %10.322.1 46.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,636428 382.0%   
Fx outflow Rs m4,368786 555.5%   
Net fx Rs m-2,732-358 762.9%   
CASH FLOW
From Operations Rs m-1,304978 -133.3%  
From Investments Rs m12,697351 3,615.4%  
From Financial Activity Rs m-301-1,099 27.4%  
Net Cashflow Rs m11,093231 4,806.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 63.9 81.1%  
Indian inst/Mut Fund % 18.2 7.5 242.7%  
FIIs % 1.0 4.9 20.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 23.7 122.8%  
Shareholders   28,591 85,207 33.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SUN PHARMA  SANOFI INDIA  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Axis Bank and ICICI Bank Surge Over 4%(12:30 pm)

Share markets in India have extended early gains and are presently trading higher. The BSE Sensex is trading up by 262 points, while the NSE Nifty is trading up by 73 points.

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

More Views on News

Most Popular

Protect Your Wealth from Fund Managers(Fast Profits Daily)

May 14, 2020

Do you know how much you are paying in fees to your mutual fund? In this video I'll share with you my views.

How Commodity Prices Tell You When Stocks Will Go Up(Fast Profits Daily)

May 20, 2020

Commodity prices often provide clues to big moves in stock markets. In today's video, I'll explain this link.

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

Why Buffet - and you - should study Quantum Liquid Fund(The Honest Truth)

May 14, 2020

Ajit Dayal on how Quantum Liquid Fund and Warren Buffett have similar investing styles.

More

Get Rich as the
Market Rebounds from Covid-19

Coronavirus Rebound
Get this special guide, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


May 27, 2020 01:39 PM

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS